Table 2.

Incidence of adverse events related to treatment over the entire study period for all evaluable patients (n = 24)

	Maximum grade per patient per event (at least possibly related), n (%)
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Hematologic adverse events
Anemia	10 (42)	8 (33)	2 (8)	0	0
Lymphopenia	0	4 (17)	1 (4)	1 (4)	0
Neutropenia	3 (13)	12 (50)	3 (13)	2 (8)	0
Thrombocytopenia	8 (33)	1 (4)	1 (4)	1 (4)	0
Leukopenia	5 (21)	5 (21)	3 (13)	2 (8)	0
Nonhematologic adverse events
Endocrine disorders
Hypothyroidism	0	1 (4)	0	0	0
Eye disorders
Eyelid function disorder	0	1 (4)	0	0	0
Gastrointestinal disorders
Constipation	0	1 (4)	0	0	0
Diarrhea	2 (8)	0	0	0	0
Dyspepsia	0	1 (4)	0	0	0
Mucositis oral	0	1 (4)	0	0	0
Nausea	1 (4)	0	0	0	0
General and administration site disorders
Fatigue	1 (4)	7 (29)	2 (8)	0	0
Infections and infestations
Bronchial infection	0	2 (8)	0	0	0
Infections and infestations	0	1 (4)	0	0	0
Lung infection	0	2 (8)	2 (8)	1 (4)	0
Mucosal infection	0	1 (4)	0	0	0
Sepsis	0	0	0	1 (4)	0
Upper respiratory infection	0	1 (4)	0	0	0
Investigations
AST increased	0	1 (4)	0	0	0
Blood bilirubin increased	0	1 (4)	0	0	0
Metabolism and nutrition disorders
Anorexia	0	1 (4)	0	0	0
Hyperglycemia	0	1 (4)	0	0	0
Hypocalcemia	0	1 (4)	0	0	0
Hypophosphatemia	0	1 (4)	0	0	0
Nervous system disorders
Peripheral sensory neuropathy	1 (4)	1 (4)	0	0	0
Syncope	0	0	1 (4)	0	0
Psychiatric disorders
Delirium	0	1 (4)	0	0	0
Respiratory, thoracic, mediastinal disorders
Dyspnea	0	0	1 (4)	0	0
Hypoxia	0	0	1 (4)	0	0
Respiratory failure	0	0	0	2 (8)	0
Skin and subcutaneous tissue disorders
Photosensitivity	0	1 (4)	0	0	0
Rash, maculopapular	0	1 (4)	1 (4)	0	0
Vascular disorders
Thromboembolic event	0	2 (8)	0	0	0

One patient was lost to follow-up.